Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Dengue

Interventions

BIOLOGICAL

rDEN3/4delta30(ME)

Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)

BIOLOGICAL

Placebo

Placebo for rDEN3/4delta30(ME)

Trial Locations (1)

Center for Immunization Research, Baltimore

All Listed Sponsors

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults | Biotech Hunter | Biotech Hunter